| Literature DB >> 29996093 |
Santhosh Karanth1, J D Adams2, Maria de Los Angeles Serrano3, Ezekiel B Quittner-Strom4, Judith Simcox5, Claudio J Villanueva5, Lale Ozcan6, William L Holland7, H Joseph Yost8, Adrian Vella2, Amnon Schlegel9.
Abstract
The common genetic variation at rs8004664 in the FOXN3 gene is independently and significantly associated with fasting blood glucose, but not insulin, in non-diabetic humans. Recently, we reported that primary hepatocytes from rs8004664 hyperglycemia risk allele carriers have increased FOXN3 transcript and protein levels and liver-limited overexpression of human FOXN3, a transcriptional repressor that had not been implicated in metabolic regulation previously, increases fasting blood glucose in zebrafish. Here, we find that injection of glucagon into mice and adult zebrafish decreases liver Foxn3 protein and transcript levels. Zebrafish foxn3 loss-of-function mutants have decreased fasting blood glucose, blood glucagon, liver gluconeogenic gene expression, and α cell mass. Conversely, liver-limited overexpression of foxn3 increases α cell mass. Supporting these genetic findings in model organisms, non-diabetic rs8004664 risk allele carriers have decreased suppression of glucagon during oral glucose tolerance testing. By reciprocally regulating each other, liver FOXN3 and glucagon control fasting glucose.Entities:
Keywords: FOXN3; fasting metabolism; glucagon; human; mouse; type 2 diabetes mellitus; zebrafish; α cell
Mesh:
Substances:
Year: 2018 PMID: 29996093 PMCID: PMC6086569 DOI: 10.1016/j.celrep.2018.06.039
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423